December 30, 2014 | The Israeli company Chiasma raised $33.8 million in a $563 million funding round, according to regulatory findings. The announcement comes some months after a $595 million commercialization deal for the company feel through. Chiasma’s main product, called oral octreotide was developed to treat acromegaly, a disorder that results from the excess growth of hormones. Current investors participating in the funding round include: MPM Capital, Abingworth, 7-Med Health Ventures LP, ARCH Venture Partners and F2 and F3 Ventures.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments